Literature DB >> 19252172

Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

Jakob R Passweg, André Tichelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19252172      PMCID： PMC2649354          DOI： 10.3324/haematol.2008.002329

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial.

Authors:  J F Tisdale; D E Dunn; N Geller; M Plante; O Nunez; C E Dunbar; A J Barrett; T J Walsh; S J Rosenfeld; N S Young
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

2.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Priscila Scheinberg; Carol Boss; Elaine M Sloand; Neal S Young
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

4.  Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia.

Authors:  Eliane Gluckman; Riitta Rokicka-Milewska; Ian Hann; Emmanouel Nikiforakis; Filipos Tavakoli; Sophie Cohen-Scali; Andrea Bacigalupo
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

5.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.

Authors:  Stephen Rosenfeld; Dean Follmann; Olga Nunez; Neal S Young
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

6.  Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Authors:  E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

Review 7.  Late clonal diseases of treated aplastic anemia.

Authors:  G Socié; S Rosenfeld; N Frickhofen; E Gluckman; A Tichelli
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

Review 8.  Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience.

Authors:  A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

9.  Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children.

Authors:  Seiji Kojima; Akira Ohara; Masahiro Tsuchida; Toru Kudoh; Ryoji Hanada; Yuri Okimoto; Takashi Kaneko; Toshikuni Takano; Koichiro Ikuta; Ichiro Tsukimoto
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113
View more
  14 in total

1.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

2.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Angélique Biancotto; Colin O Wu; Neal S Young
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

3.  Effect of Tianshengyuan-1 (TSY-1) on telomerase activity and hematopoietic recovery - in vitro, ex vivo, and in vivo studies.

Authors:  Su Lu; Xiaotian Qin; Shaopeng Yuan; Yawei Li; Liming Wang; Yusheng Jin; Gang Zeng; Lawrence Yen; Jenny Hu; Tracie Dang; Sophie Song; Qi Hou; Jianyu Rao
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 4.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 5.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Blood Adv       Date:  2018-11-13

6.  Type I IFNs Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during Pneumocystis Lung Infection in Mice.

Authors:  Justin R Prigge; Teri R Hoyt; Erin Dobrinen; Mario R Capecchi; Edward E Schmidt; Nicole Meissner
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

7.  Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next?

Authors:  Sujith Samarasinghe; Judith Marsh; Carlo Dufour
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 8.  Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Authors:  Aaron T Gerds; Bart L Scott
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

9.  Clinical outcomes in adult patients with aplastic anemia: A single institution experience.

Authors:  Prajwal Boddu; Guillermo Garcia-Manero; Farhad Ravandi; Gautam Borthakur; Elias Jabbour; Courtney DiNardo; Nitin Jain; Naval Daver; Naveen Pemmaraju; Paolo Anderlini; Simrit Parmar; Devendra Kc; Mary Akosile; Sherry A Pierce; Richard Champlin; Jorge Cortes; Hagop Kantarjian; Tapan Kadia
Journal:  Am J Hematol       Date:  2017-09-25       Impact factor: 10.047

Review 10.  Aplastic anemia: pathophysiology and treatment.

Authors:  Neal S Young; Andrea Bacigalupo; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-24       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.